184What is the inhibitory effect of cabozantinib on bone metastasis?

Cabozantinib, an oral multi-target anticancer drug, has attracted widespread attention in the field of tumor treatment in recent years. In particular, its application effect in the treatment of bone metastases has attracted much attention. Cabozantinib is a polyphenol oxidase inhibitor and a multi-target tyrosine kinase inhibitor that can inhibit the growth, differentiation and proliferation of tumor cells. The targets it inhibits include MET, VEGFR1/2/3, ROS1, RET, AX L, NTRK, KIT and so on at least 9. This multi-target inhibitory effect allows cabozantinib to show significant efficacy in a variety of tumors, especially in the treatment of bone metastases.

In one study, cabozantinib achieved disease control rates of 76%, 71%, and 58% in patients with bone metastases from liver cancer, prostate cancer, and ovarian cancer, respectively. Disease control rates for bone metastases in melanoma, breast cancer, and non-small cell lung cancer were 45%, 45%, and 40%, respectively. These data fully demonstrate the effectiveness of cabozantinib in the treatment of bone metastases.

Cabozantinib can not only effectively control the progression of bone metastasis, but also reduce symptoms such as bone pain caused by bone metastasis, thereby improving the patient's quality of life. This has been confirmed in multiple clinical studies.

Compared with other traditional bone metastasis treatment drugs, cabozantinib has shown superiority in terms of disease control rate and symptom improvement. Its multi-target inhibitory effect enables it to more comprehensively control tumor growth and metastasis.

Although cabozantinib has shown significant efficacy in the treatment of bone metastases, it also has certain side effects. Common adverse events include fatigue, diarrhea, skin toxicity, and hypertension. However, most of these adverse events were mild to moderate and could be controlled with appropriate dose adjustment or symptomatic treatment. Therefore, cabozantinib remains a treatment option worth considering when weighing efficacy versus safety.